IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10)
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Mechanisms associated with epigenetic regulation have recently been shown to be implicated in the pathogenesis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). For instance, mutations of the isocitrate dehydrogenase gene (IDH) have a role in AML and other types of cancer through altered cellular respiration.
1 IDH1 at chromosome band 2q33.3 and IDH2 at 15q26.1 encode metabolic enzymes active in the tricarboxylic cycle catalyzing the oxidative decarboxylation of isocitrate into a-ketoglutarate. Gain-of-function mutations of IDH1 and IDH2 leads to the production and accumulation of 2-hydroxyglutarate, which in turn causes disturbed gene expression profiles through dysregulated epigenetic function. 1 Recurrent mutations of IDH1 and IDH2 have been reported in 5-15% of patients with de novo AML. [2] [3] [4] [5] Mutated IDH strongly associates with a normal karyotype 2, 6 in AML and with trisomy 8 in AML and MDS in a few studies. 3, 7 IDH1 and IDH2 mutations are common in patients with mutations of the nucleophosmin gene (NPM1), 2, 6 the runt-related transcription factor 1 gene (RUNX1) 8 and the mixed-lineage leukemia gene (MLL-PTD). 6 To evaluate the frequency of IDH1/2 mutations in therapyrelated MDS (t-MDS) and AML (t-AML) and their possible association to type of previous therapy, to leukemic transformation from t-MDS to t-AML and to other genetic abnormalities, 140 previously published patients with t-MDS and t-AML 9 were analyzed. Mononuclear cells isolated from the bone marrow or blood at diagnosis of 89 patients with t-MDS and of 51 patients with overt t-AML were included in the study. All patients were previously karyotyped and investigated for mutations of FLT3 (ITD, TKD), KIT, JAK2, KRAS, NRAS, BRAF, PTN11, RUNX1, MLL (PTD), CEBPA, NPM1 and TP53.
9 Screening for IDH mutations was performed by means of amplification of the fourth exon of IDH1 and IDH2, followed by high-resolution melting (HRM) analysis. Possible sequence variations identified by HRM were confirmed by Sanger sequencing.
Mutations in exon 4 of IDH1 or IDH2 were detected in 12 of 140 patients with t-MDS/t-AML (9%). Detailed clinical, genetic and cytogenetic characteristics for each of the 12 cases with IDH1/2 mutations are shown in Table 1 . In our study, 9 of 12 patients displayed mutations of IDH2, as opposed to only 3 of 12 patients with mutations of IDH1. This is in agreement with other studies, in which IDH2 mutations have been found to be more prevalent in AML. 2, 3 Half of the patients with mutated IDH harbored the IDH2 R140Q mutation, the most common type in de novo AML. 2, 3 All IDH mutations detected in the present study were heterozygous, indicating a dominant effect in leukemogenesis. 1 None of the patients had concurrent mutations in IDH1 and IDH2.
IDH1/2 mutations were observed with a frequency of 7% in t-MDS and 12% in t-AML (Table 1) . These frequencies are similar to the 5-15% reported in studies of de novo AML 2,3 and 5% in de novo MDS. 4 Only one study has so far investigated IDH mutations in overt t-AML; Pichler et al. 5 reported on IDH mutations in 5% of 73 patients with t-AML. The discrepancy in frequency of IDH mutations between the present study and the study by Pichler may be explained by a different selection of patients and thus a different distribution of cytogenetic abnormalities in the two cohorts. Table 2 outlines important characteristics of the 12 IDH mutated cases in comparison with the 128 cases with non-mutated IDH. No significant association could be established between the occurrence of IDH mutations and previous genotoxic therapy with alkylating agents, topoisomerase II inhibitors or radiotherapy (Table 2) . However, IDH mutations were significantly associated with transformation from MDS to AML as five out of six patients with t-MDS and IDH mutations progressed to AML ( Abbreviations: 4-epi-dox, 4-epi-doxorubicin; 6-MP, 6 mercaptopurine; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; Asp, l-asparaginase; Aza, azathioprine; BOPP, carmustine þ vincristine þ procarbazine þ prednisone; CCNU, lomustine; CLB, chlorambucil; CTX, cyclophosphamide; CVPP, lomustine þ vinblastine þ procarbazine þ prednisone; Dox, doxorubicin; F, female; IDH, isocitrate dehydrogenase gene; IgA, immunoglobulin A; M, male; MDS, myelodysplastic syndrome; MELPH, melphalan; Mtx, methotrexate; MLL-PTD, mixed-lineage leukemia gene; NHL, non-hodgkin lymphoma; NPM1, nucleophosmin gene; Pred, Prednisone; RT, radiotherapy; RUNX1, runt-related transcription factor 1 gene; t-AML, therapy-related AML; t-MDS, therapy-related MDS; VCR, vincristine.
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IDH mutations were significantly associated with a normal karyotype (P ¼ 0.006, Table 2 ), similar to observations from de novo disease. 2, 6 IDH mutations have also been shown to be correlated to isolated trisomy 8 in de novo MDS and AML. 3, 7 Although three patients with IDH mutations in our study had trisomy 8 as part of a complex karyotype, the association did not reach statistical significance (Table 2) . Interestingly, a novel significant association was observed between IDH mutations and der(1;7)(q10;p10) (P ¼ 0.008, Table 2 ), whereas IDH mutations were inversely correlated with other chromosome 7 abnormalities (P ¼ 0.0028, Table 2 ). This correlation was not observed by Pichler et al., who did not have any patients with der(1;7)(q10;10) in their study of t-AML.
The unbalanced translocation der(1;7)(q10;p10) resulting in trisomy 1q and loss of 7q is a characteristic recurrent cytogenetic abnormality in MDS and AML particularly frequent in therapyrelated disease following treatment with alkylating agents. 11, 12 The association between IDH mutations and der(1;7) may indicate that der(1;7)(q10;p10) belongs to a specific subgroup, biologically distinct from other chromosome 7 abnormalities, and suggests that trisomy 1q may be of importance in leukemogenesis. This is further supported by another patient with IDH mutation in our study (case 36) who had an unbalanced translocation, der(6)t(1;6)(q?25;p21), resulting in partial gain of a large part of 1q, but normal chromosomes 7 (Table 1) . Consistent with our findings, a different clinical outcome has been reported between MDS patients with der(1;7)(q10;p10) and patients with À 7/7q À 13 although other studies have been unable to confirm this difference. 12, 14 Other gene mutations have been shown as common in IDH1/2 mutated cases of de novo AML. 2, 6, 8 In our cohort, 7 of 12 patients with IDH mutations displayed mutations of RUNX1 (n ¼ 3), NPM1 (n ¼ 2), FLT3, NRAS and MLL-PTD (one case each; Table 1 ). However, no statistically significant correlation could be established between these mutations and mutations of IDH1/2, possibly due to the small number of cases ( Table 2 ). The lack of association between IDH mutations and either class I mutations (accelerating proliferation) or II mutations (impairing differentiation), supports current suggestions that IDH belongs to a novel class of mutations involved in epigenetic regulation. 6 Based on cytogenetic characteristics, we have previously discussed different genetic pathways 9, 15 in t-MDS/t-AML. Patients with IDH mutations seem to cluster in two pathways. The first, pathway I is defined by À 7/7q À but normal chromosomes 5 and are often associated with RUNX1 mutations and with methylation of CDKN2B (p15). The second, pathway VII comprises patients with a normal karyotype frequently presenting mutations of NPM1, FLT3 and RAS. A combination of trisomy 1q, mutation of IDH, and perhaps mutation of RUNX1 could represent a new specific pathway in t-MDS/t-AML.
In conclusion, mutations of IDH1/2 are of the same type and occur at the same frequency in therapy-related and de novo MDS and AML. They are unrelated to type of previous therapy, but are significantly associated with leukemic transformation. Furthermore, they are associated with a normal karyotype and with der(1;7)(q10;p10), but are inversely correlated to other chromosome 7 abnormalities. This suggests a specific biological effect in leukemogenesis different from that of other chromosome 7 defects perhaps linked to trisomy 1q. It has been demonstrated in mice that enhanced tonus of vegetative nervous system regulates mobilization of hematopoietic stem and progenitor cells (HSPCs) into peripheral blood (PB). It is well known that HSPCs circulate under steady-state conditions at detectable levels in PB, with their numbers increasing in response to stress, inflammation, and tissue and organ injury. [1] [2] [3] Circulation of these cells under normal steady-state conditions is regulated by a circadian rhythm, with the peak of these circulating cells occurring in the early morning hours and the nadir at night. [1] [2] [3] [4] As observed in mice exposed to daylight changes, this oscillation in HSPC levels is affected as postulated by changes in tonus of the vegetative nervous system. 4, 5 HSPCs can be also mobilized into PB in an enforced manner by administration of granulocyte-colony stimulating factor (G-CSF), and it has also been shown in mice that release of these cells into PB depends critically on the vegetative nervous system. 4, 5 Moreover, UDP-galactose:ceramide galactosyltransferase-deficient mice, which exhibit aberrant nerve conduction and do not release norepinephrine (NE) into the bone marrow (BM) microenvironment, do not mobilize HSPCs in response to G-CSF. 4 To explain how NE signaling influences HSPC mobilization, it has been postulated that it modulates expression of stromal derived factor-1 (SDF-1) in the BM microenvironment, and such a mechanism would be consistent with the finding that administration of b2-adrenergic agonists enhances mobilization of HSPCs in both control and NE-deficient mice. 4 In a recent study, it has also been proposed that G-CSF increases sympathetic tonus directly via G-CSF receptors that are expressed on peripheral sympathetic neurons, which would reduce NE reuptake and increase NE availability in the BM microenvironment. 
